Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

Background: Scarce data exist that analyze the outcomes of hematological patients with SARS-CoV-2 infection during the Omicron variant period who received treatment with remdesivir or nirmatrelvir/ritonavir. Methods: This study aims to address this issue by using a retrospective observational regist...

Full description

Bibliographic Details
Main Authors: José Luis Piñana, Inmaculada Heras, Tommaso Francesco Aiello, Irene García-Cadenas, Lourdes Vazquez, Javier Lopez-Jimenez, Pedro Chorão, Cristina Aroca, Carolina García-Vidal, Ignacio Arroyo, Eva Soler-Espejo, Lucia López-Corral, Alejandro Avendaño-Pita, Anna Arrufat, Valentín Garcia-Gutierrez, Elena Arellano, Lorena Hernández-Medina, Clara González-Santillana, Julia Morell, José Ángel Hernández-Rivas, Paula Rodriguez-Galvez, Mireia Mico-Cerdá, Manuel Guerreiro, Diana Campos, David Navarro, Ángel Cedillo, Rodrigo Martino, Carlos Solano
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Viruses
Subjects:
remdesivir
nirmatrelvir/ritonavir
molnupiravir SARS-CoV-2 vaccines
Omicron
respiratory virus
hematological malignancies
Online Access:https://www.mdpi.com/1999-4915/15/10/2066

Internet

https://www.mdpi.com/1999-4915/15/10/2066

Similar Items